Patrick Donnelly logo

Patrick Donnelly


Pat is a highly successful entrepreneur in the Pharmaceutical Services sector. As CEO, Pat has built and led three companies to successful exits including Advarra, (leading North American IRB), Aptiv Solutions (global clinical development services company), and PRA International (leading global full-service CRO).

Richard Shea logo

Richard Shea


Mr. Shea joined Rediscovery Life Sciences as CEO in 2019. He is an experienced life sciences entrepreneur and has been involved in the creation and growth of multiple life science start-ups over the last 20 years. Mr. Shea also serves as CEO of Basking Biosciences. Mr. Shea was CEO of Vascular Pharmaceuticals from 2010-2017 and advanced its development candidate through the completion of Phase 2 in diabetic kidney disease.

Rick Schnellman, PhD logo

Rick Schnellman, PhD

Founder, Chief Scientific Officer

Rick is Dean of the University of Arizona College of Pharmacy and a founder of RLS. He is a leading pharmacologist, researcher, and drug discovery entrepreneur. Rick joined UA in August 2016 from the Medical University of South Carolina (MUSC). At MUSC, Rick chaired the college’s Department of Drug Discovery and Biomedical Sciences from 2001 to 2015, and his research led to the discovery of the renal protective effects of suramin.

Greg Johnson logo

Greg Johnson

Director, Program Management

Greg Johnson has more than 25 years of experience in Biotech and Clinical Research, with recognized expertise in strategic planning, project management, and operations management, as well as in electronic data capture and the implementation and use of computerized systems in a clinical research setting. Mr. Johnson is a principal with Cagley Johnson Consulting Inc. Prior to founding his consulting company, he served as Chief Operating Officer, then President and Chief Financial Officer, for MedGenesis Therapeutix (2007-2017).

James Tumlin logo

James Tumlin

Senior Medical Advisor

Dr. Tumlin is a Professor of Medicine and Nephrology with Emory University and the lead investigator for Georgia Nephrology Research Institute. He is on the editorial board of numerous journals, including the Clinical Journal of the American Society of Nephrology and Kidney International, and has authored over 100 peer-reviewed manuscripts. Dr. Tumlin has led clinical studies in a broad range of nephrology-related conditions including acute kidney injury (AKI), all stages of chronic kidney disease (CKD), Sepsis, and ICU medicine. He is an internationally recognized clinical trialist.